



# SHAPING THE FUTURE

of Clinical Research Innovation



322 North Shore Drive  
Building 1B, Suite 200, #362  
Pittsburgh, PA 15212-5875

[www.aaci-cancer.org](http://www.aaci-cancer.org)



18th Annual AACI CRI Meeting  
**June 23-25, 2026**

Loews Chicago O'Hare Hotel • Rosemont, IL



# AACI CRI 2026 Steering Committee

**Chair: Margaret "Margie" Kasner, MD, MSCE**  
Sidney Kimmel Comprehensive Cancer Center at Jefferson

**Dina Aziz, MS**  
The University of Texas MD Anderson Cancer Center

**Stefanie M. Belanger, MHA, CCRP**  
Duke Cancer Institute

**Sarah Bigelow, CCRP**  
Tulane Cancer Center, Louisiana Cancer Research Center

**Angela Campbell, MS**  
The Ohio State University Comprehensive Cancer Center  
- The James

**Mario M. Contreras, MBA, MSN, RN**  
Indiana University Melvin and Bren Simon  
Comprehensive Cancer Center

**Whitney Ballard Cunningham, MS, SHRM-CP**  
UK Markey Cancer Center

**Anthony El-Khoueiry, MD**  
USC Norris Comprehensive Cancer Center

**Muhammad Furqan, MD**  
Stephenson Cancer Center, University of Oklahoma

**Edward J. Kim, MD, PhD**  
UC Davis Comprehensive Cancer Center

**Jay A. Lebsack, MA**  
Moffitt Cancer Center

**Amy M. Overby**  
Fred & Pamela Buffett Cancer Center

**Jennifer F. Rogers, MBA**  
UK Markey Cancer Center

**Julie C. Schaum, MS**  
Vanderbilt-Ingram Cancer Center

**Lauren Wall, MS**  
The University of Chicago Medicine  
Comprehensive Cancer Center

## Meeting App and Social Media

The agenda, presentations, exhibitor information, and attendees list are available on the meeting app.

To access the app on your mobile device:

- Download "Cvent Events" from your mobile app store.
- Within the Cvent Events app, search for "18th Annual AACI Clinical Research Innovation Meeting" and download the meeting.
- Log in with the name and email used during registration.
- You will receive a 6-digit verification code. Enter your code and log in.

Presentations and session recordings can be accessed using the desktop version of the app: <https://cvent.me/drZD84>

**Wireless Network: AACI CRI**

**Password: aaci2026**

Please engage with AACI on the following social media platforms and use hashtag **#CRI2026**. We look forward to seeing your photos and meeting insights!

**Bluesky/Facebook/Instagram/Threads: @AACICancer**

**LinkedIn: @aaci-cancer**

**X: @AACI\_Cancer**

# AACI CRI Shaping the Future of Clinical Research Innovation

The Association of American Cancer Institutes (AACI) Clinical Research Innovation (CRI) program provides a forum for research leaders at AACI cancer centers to develop and share best practices for the efficient operation of clinical trials offices (CTOs). The 18th Annual AACI CRI Meeting, "Shaping the Future of Clinical Research Innovation," fosters opportunities for peer-to-peer networking and collaboration across cancer centers, industry, and government health agencies.

## Meeting Objectives

- Apply real-world data and artificial intelligence (AI) tools to improve cancer clinical trial feasibility, patient recruitment, and equity
- Streamline cancer clinical trial start-up, enhance communication, and accelerate study activation without compromising quality
- Support staff readiness, retention, and operational excellence in CTOs through training, onboarding, and mentorship
- Align cross-departmental workflows to ensure regulatory and operational consistency in complex clinical trials
- Learn budgeting, reimbursement, and funding models to maintain compliance, long-term sustainability, and data integrity in CTOs
- Explore industry-cancer center collaborations to expand patient inclusion, decentralize trials, and improve reimbursement models in clinical research
- Identify key features of efficient multisite cancer trials, including standardized operations, principal investigator oversight, and investigational drug logistics

# AACI CRI Meeting

## Who Attends This Meeting?

- Individuals from AACI member cancer centers, including:
  - CTO administrative directors, medical directors, managers, and supervisors
  - Deputy/associate directors of clinical research administration
  - Cancer center administrators
  - Research regulatory managers and staff
  - Clinical research finance directors, managers, and supervisors
  - Biostatisticians and informatics specialists
- Employees of U.S. Department of Health and Human Services agencies and offices, including the National Cancer Institute and the U.S. Food and Drug Administration
- AACI Sustaining Members
- AACI Corporate Roundtable and Tech Gold members
- Representatives from industry, including drug development companies, clinical research organizations, and consultants
- Information technology companies that support cancer center clinical research management
- Like-minded organizations promoting patient access to clinical trials

## MEETING PROGRAM

### 18th Annual AACI Clinical Research Innovation (CRI) Meeting *Shaping the Future of Clinical Research Innovation*

Tuesday, June 23–Thursday, June 25 • Loews Chicago O'Hare Hotel, Rosemont, IL

All sessions are in central time. Sessions are held in Cassatt Ballroom unless otherwise noted.

#### Tuesday, June 23

**10:00 AM** **Registration Opens** Artist Foyer

**11:00 AM** **Exhibits Open** Artist Foyer

**11:00 AM** **AACI Tech Gold | IgniteData Archer: One Platform. Every Study.**

*Presented by IgniteData and Advarra*

*Warhol*

Your coordinators are still re-keying EHR data into a different EDC for every sponsor, IIT, and multisite trial. IgniteData and Advarra are ending that. IgniteData's Archer is a SMART-on-FHIR app that pulls regulatory-grade data straight from the source, whether you use Epic, Cerner, OncoEMR, or something else. It delivers that data into any EDC the trial demands while keeping the coordinator securely in the loop. Backed by peer-reviewed JAMIA Open research, Archer is currently live across a six-country research network and trusted by 47 percent of NCI-Designated Comprehensive Cancer Centers. Join leaders from IgniteData and Advarra to see the data transfer come to life from EHR into EDC, and learn how one unified workflow empowers your site take on more without adding headcount.

**12:15 PM** **Welcome**

**Margie Kasner, MD, MSCE**

*Sidney Kimmel Comprehensive Cancer Center at Jefferson*

**Joann B. Sweasy, PhD**

*Fred & Pamela Buffett Cancer Center*

**12:30 PM A Dose of Healthcare Humor: the Perfect Prescription for Less Stress and More Success**

*Supported by Advarra*

Just look around the average workplace and you'll see most professionals dealing with lots of stress.

Well, the good news is that there's a successful strategy to approach these challenges. Hall of Fame Speaker David Glickman will show you how by simply changing your perspective you'll experience a profound way of handling these frustrations.

And this program isn't so much a traditional speech as it is a full-blown, high-energy one-man show. It's got observational humor, funny visuals, hilarious song parodies, and a big "rock and roll" finish!

**Moderator: Margie Kasner, MD, MSCE**

*Sidney Kimmel Comprehensive Cancer Center at Jefferson*

**David Glickman, CSP, CPAE**

**Jennifer Mead**

*Advarra*

---

**1:30 PM Team Science in Action: Co-Managing Multidisciplinary Trials Across Oncology and Non-Oncology**

As clinical trials increasingly span therapeutic areas and specialties, effective co-management across oncology and non-oncology departments is critical to success. This panel will explore how teams are collaboratively leading multidisciplinary studies that require shared oversight, integrated workflows, and coordinated operational support. Panelists will discuss strategies for aligning leadership, regulatory processes, and day-to-day trial execution across departments.

**Moderator: Sarah Bigelow, CCRP**

*Tulane Cancer Center, Louisiana Cancer Research Center*

**Julia Rasmussen, MS, BSN, RN**

*Duke Cancer Institute*

**Caterina Vacchi-Suzzi, PhD, CCRP**

*Stony Brook Cancer Center*

**Erin Winters, RN, BSN, BMTCN**

*The University of Kansas Cancer Center*

**2:30 PM Networking Break** *Artist Foyer*

**3:00 PM Driving Faster and Smarter Study Start-up**

Efficient study start-up is critical to launching cancer clinical trials on time and on budget. Speakers will share insights on overcoming common barriers and implementing process improvements that improve communication and enhance both speed and quality in study activation. Attendees will leave with actionable ideas to strengthen collaboration across research teams.

**Moderator: Amy M. Overby**

*Fred & Pamela Buffett Cancer Center*

**Ankeeta Joshi, CCRC**

*Laura and Isaac Perlmutter Cancer Center at NYU Langone Health*

**Erin Monari, PhD, CCRP**

*UF Health Cancer Institute*

**Ajay Nooka, MD, MPH, FACP**

*Winship Cancer Institute at Emory University*

---

**4:00 PM Poster Session** *Avedon Ballroom*

**4:30 PM AACI Tech Gold | Operational Excellence: Real-World Lessons in EHR-to-EDC Integration**

*Presented by Medidata*

*Pollock*

Transforming clinical research requires moving past the promise of connectivity and into the reality of site-level execution. This session cuts through the technical jargon to focus on the operational lived experience of those on the front lines. Join a distinguished panel of site representatives as they share firsthand accounts of implementing Medidata Health Record Connect to automate the flow of data from the EHR directly into Rave.

This isn't a high-level overview; it is a candid exploration of the real-life implementation journey. Our speakers will pull back the curtain on the logistical hurdles and triumphs of scaling interoperability across diverse therapeutic areas.

---

**5:30 PM Welcome Reception**

*Hosted by AACI*

*Artist Foyer*

## Wednesday, June 24

**7:00 AM Breakfast** *Avedon Ballroom*

---

**7:00 AM CTO Administrative Directors Breakfast** *(Invitation only)*  
*Prado*

---

**7:00 AM CTO Medical Directors Breakfast** *(Invitation only)*  
*Metropolitan*

---

**8:00 AM Exhibits Open** *Artist Foyer*

---

**8:15 AM Welcome Day 2: State of the Union**

**Margie Kasner, MD, MSCE**

*Sidney Kimmel Comprehensive Cancer Center at Jefferson*

---

**8:30 AM Building Strong Foundations: Training, Onboarding, and Mentorship in Clinical Trials Offices**

Speakers will highlight strategies for preparing faculty and research staff to manage the complex demands of clinical research through structured onboarding and ongoing professional development. Discussion will also address how intentional mentorship and continuous learning promote staff retention, compliance, and operational excellence.

**Moderator: Whitney Cunningham, MS, SHRM-CP**

*UK Markey Cancer Center*

**Stephanie Brogan, CCRP**

*Dana-Farber Cancer Institute, Harvard Medical School*

**Andrea Skafel, MSc, CCRP**

*UCSF Helen Diller Family Comprehensive Cancer Center*

**Theresa L. Werner, MD**

*Huntsman Cancer Institute at the University of Utah*

---

**9:30 AM Leveraging Real-World Data for Smarter Trial Design and Patient Identification**

As real-world data (RWD) from electronic health records (EHRs) and registries become more accessible, cancer clinical trials offices are finding new ways to design smarter studies and identify patients faster. Panelists will explore how teams are mining EHRs, applying AI-driven matching tools, and operationalizing real-world evidence to enhance trial feasibility, recruitment, and equity. They will also share lessons on integrating RWD into institutional workflows and navigating the contracts and data-sharing processes that enable effective collaboration across sites and sponsors.

**Moderator: Muhammad Furqan, MD**

*Stephenson Cancer Center, University of Oklahoma*

**Wencesley Paez, MD, MS**

*Fox Chase Cancer Center, Temple Health*

**Aashka Shah, MHA**

*Memorial Sloan Kettering Cancer Center*

**Evan Sholle, MS**

*Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine*

**10:30 AM Break** *Artist Foyer*

**10:45 AM Breakout Sessions**

**Advancing Artificial Intelligence (AI) in Cancer Research**  
*Guggenheim Ballroom 1*

The session will highlight emerging practices for integrating AI into existing processes and fostering collaboration across institutions. Participants will discuss how AI tools are being applied, where they have added value, and where gaps remain. Through common use cases, they will identify areas for additional training or support to advance responsible use of AI in clinical research.

**Aligning Trial Portfolio Strategy With Institutional Cancer Priorities**

*Guggenheim Ballroom 2*

Panelists will discuss how academic cancer centers align clinical trial portfolios with disease-based priorities and institutional goals. They will also share tools used to inform decision-making, monitor performance, and support transparent conversations with institutional leadership.

**Building Effective Leadership Programs in Cancer Centers**  
*Guggenheim Ballroom 3*

Presenters will explore how cancer centers develop and implement leadership and change management programs to support organizational transformation. They will highlight structures, competencies, and training models that equip leaders to manage complexity, drive adoption of new initiatives, and align teams around strategic priorities.

## 10:45 AM Breakout Sessions

### Coordinating Multisite Investigator-Initiated Trials

*Louvre Ballroom 1*

Attendees will discuss common challenges in coordinating multisite investigator-initiated trials, including operational, regulatory, and communication considerations across participating sites. They will leave with takeaways they can apply to their own centers to improve coordination, efficiency, and trial execution from start-up through closeout.

### Expanding Research Access

*Louvre Ballroom 2*

Speakers will discuss hub-and-spoke network models as a strategy for extending clinical research access to rural and underserved communities. They will address operational, regulatory, and financial considerations for building and sustaining networks, including site selection, oversight, staffing, and data quality. Real-world examples will highlight effective approaches to engaging rural partners, reducing barriers to participation, and strengthening collaboration across networks.

### Five-Minute Wins

*Louvre Ballroom 3*

This interactive breakout session will feature rapid, five-minute presentations highlighting recent successes at AACI cancer centers. Facilitators will guide the session and keep speakers on time using a visible timer.

### Strengthening Oversight

*Warhol*

Presenters will explore operational strategies for Protocol Review and Monitoring Committees and Data and Safety Monitoring Committees in clinical research. They will discuss approaches to effective protocol review, ongoing study oversight, risk management, and ensuring participant safety, while maintaining trial integrity.

### Study Activation in Practice

*Cassatt Ballroom*

Speakers will discuss critical components of clinical trial activation and highlight practical tools and resources that can improve operational efficiency and strengthen communication among stakeholders. They will also share approaches to accelerate trial launch and enrollment.

11:45 AM **Lunch** *Avedon Ballroom*

## 12:30 PM AACI Tech Gold | From Wish List to Workflow: Reimagining Site-to-Sponsor Imaging Connectivity

*Presented by Yunu*

*Warhol*

What if clinical trial imaging workflows worked the way sites and sponsors need them to?

Today, source imaging data is often trapped in disconnected systems, spreadsheets, manual exports, and follow-up emails, creating delays, duplicate work, and limited visibility. Attendees are invited to bring their wish lists and reimagine a more connected site-to-sponsor workflow in which data is accessible, traceable, and actionable in real time.

Presenters and participants will explore common friction points in clinical trial imaging operations, identify opportunities to reduce manual burden, and discuss what direct, bidirectional connectivity between sites and sponsors could enable.

---

## 1:15 PM Partnering for Progress: Strengthening Industry-Cancer Center Collaborations in Clinical Trials

Join AACI Corporate Roundtable members for an engaging conversation on the evolving landscape of clinical trials. Panelists will discuss opportunities for expanding patient inclusion, decentralizing trials, and improving reimbursement models. Attendees are invited to share their own ideas for making research more accessible and patient centered through collaboration.

**Moderator: Jay Lebsack, MA**

*Moffitt Cancer Center*

**Kate Boneck**

*Merck*

**Thea McNeill**

*AbbVie*

**Bethany Ann Strother**

*Lilly*

---

## 2:15 PM Breakout Sessions

### **Bridging the Gap: Integrating Community Engagement and Data Management With Clinical Trials**

*Guggenheim Ballroom 1*

Speakers will explore how community outreach and engagement offices and clinical protocol and data management teams can work collaboratively with clinical trials offices to enhance efforts with trial recruitment, ensuring accurate and timely data management, and improving cross-team communication.

### **Five-Minute Wins**

*Guggenheim Ballroom 2*

This interactive breakout session will feature rapid, five-minute presentations highlighting recent successes at AACI cancer centers. Facilitators will guide the session and keep speakers on time using a visible timer.

### **Inside the CCSG**

*Guggenheim Ballroom 3*

Moderators will provide invaluable guidance on the National Cancer Institute's Cancer Center Support Grant (CCSG) from cancer center leaders who have recently submitted applications. Participants will share what they've learned from preparing for site visits and will conduct a deep dive into specific reporting sections of the CCSG.

### **Integrating Artificial Intelligence (AI) in Cancer Research**

*Cassatt Ballroom*

The session will highlight emerging practices for integrating AI into existing processes and fostering collaboration across institutions. Participants will discuss how AI tools are being applied, where they have added value, and where gaps remain. Through common use cases, they will identify areas for additional training or support to advance responsible use of AI in clinical research.

### **Lessons Learned for Onboarding and Training**

*Louvre Ballroom 1*

Staff onboarding and training in clinical trials offices has been a topic of ongoing discussion as cancer centers seek to improve efficiency, compliance, and staff readiness. Speakers will share proven approaches that have worked in their centers, including comprehensive onboarding programs, ongoing training initiatives, and methods to assess staff competency.

### **Reducing Time to Activation**

*Louvre Ballroom 2*

This session will explore strategies to reduce time to trial activation, with a focus on how protocol amendments impact study start-up timelines. To guide the discussion, attendees will review key insights from an AACI CRI position paper on protocol amendments.

## Quality Assurance in Clinical Research

*Louvre Ballroom 3*

Participants will share common quality assurance (QA) challenges and discuss standard operating practices, effective risk assessment tools, methods for identifying discrepancies, and continuous improvement strategies. This interactive forum provides a space to brainstorm approaches to elevating QA processes.

### **Sustaining Investigator Engagement**

*Warhol*

Speakers will discuss strategies to increase and maintain investigator engagement in clinical research, focusing on policies for incentivizing participation, recognizing contributions, and supporting investigators' academic advancement. Attendees will leave with approaches for fostering environments where investigators can thrive while advancing research goals and maintaining institutional priorities.

## 3:15 PM Networking and Dessert Break

*Artist Foyer*

## 3:45 PM 2026 CRI Abstract Presentations

The Clinical Research Innovation (CRI) Steering Committee has selected four abstracts for presentation that illuminate clinical research challenges and solutions. The abstract presentations will be followed by a Q&A session.

### **Moderator: Margie Kasner, MD, MSCE**

*Sidney Kimmel Comprehensive Cancer Center at Jefferson*

### **Anshini Bhatt, MBBS, MPH**

*Laura and Isaac Perlmutter Cancer Center at NYU Langone Health*

### **Marjorie Brelsford, MHA, CCRP**

*Moffitt Cancer Center*

### **Kate McCaffrey, MBA**

*Moffitt Cancer Center*

### **Erin Monari, PhD, CCRP**

*UF Health Cancer Institute*

### **Liliana Will, DDS, MPH**

*OHSU Knight Cancer Institute*

## 4:45 PM Tech Connect | AI Enabled Pre-Screening and Patient Identification at Scale (Invitation only)

**Presented by Triomics**

*Pollock*

Speakers from Holden Comprehensive Cancer Center, University of Iowa who have been actively deploying the Triomics Prism technology will share improvements they have seen in reducing manual chart review, coordinator screening time, and ensuring every patient is screened against every active trial in the portfolio.

**5:00 PM Tech Connect | Happy Hour** *(Invitation only; registration required)*  
**Presented by Veeva**  
*Ice Bar*

Join Veeva for drinks and light appetizers in a relaxed atmosphere. Visit Veeva's exhibit booth to learn more.

## Thursday, June 25

**7:00 AM Breakfast** *Avedon Ballroom*

**8:00 AM Exhibits Open** *Artist Foyer*

**8:00 AM Equitable Access to Clinical Trials (EACT) Project Update**

A representative will provide an overview of recent developments and upcoming priorities for the EACT initiative.

**Erin Williams, MBA**  
*Simmons Comprehensive Cancer Center*  
*UT Southwestern Medical Center*

**8:15 AM Finance 101: Strategies for Reimbursement, Funding, and Compliance**

Panelists will break down the essentials of finances for clinical trials offices, from reimbursement models and budgeting frameworks to funding strategies for investigator-initiated trials, industry partnerships, and cooperative studies. They will also share how their institutions are educating faculty and staff to ensure data integrity and compliance with sponsor requirements. Attendees will leave with practical advice for sustaining research programs amid an evolving funding landscape.

**Moderator: Lauren Wall, MS**  
*The University of Chicago Medicine Comprehensive Cancer Center*

**Ronni Hayes, MBA, CPC**  
*UAMS Winthrop P. Rockefeller Cancer Institute*

**Bhuvana Ramachandran, MS, MBA, MPH**  
*Stanford Cancer Institute*

**Coleman Tew, MPA**  
*UNC Lineberger Comprehensive Cancer Center*  
*University of North Carolina at Chapel Hill*

**9:15 AM Advancing Cancer Research Beyond the Main Center**

Expanding clinical trials to regional sites brings new opportunities – and new challenges. Leaders from operations, pharmacy, and community research will share insights to help teams deliver efficient multisite cancer trials, highlighting real-world strategies for standardizing operations, ensuring strong principal investigator oversight, and managing the logistics of investigational drug transport.

**Moderator: Edward J. Kim, MD, PhD**  
*UC Davis Comprehensive Cancer Center*

**Rebecca Arend, MD**  
*O'Neal Comprehensive Cancer Center at the*  
*University of Alabama at Birmingham*

**Kristin Bialobok, MSN, RN**  
*UPMC Hillman Cancer Center*

**Kristen Kipping-Johnston, MPH, CCRP**  
*The University of Chicago Medicine Comprehensive Cancer Center*

**10:15 AM Break** *Artist Foyer*

**10:30 AM Seeking Clarity for the CCSG and Beyond**

Panelists will provide an overview of the National Cancer Institute (NCI) Cancer Center Support Grant (CCSG), including key components, priorities, and considerations for cancer centers. Participants will also hear updates from the NCI on current initiatives, policies, and developments impacting the cancer research and clinical trials landscape.

**Moderator: Julie Schaum, MS**  
*Vanderbilt-Ingram Cancer Center*

**Krzysztof Ptak, PhD**  
*National Cancer Institute*

**11:30 AM Closing Remarks**

**Margie Kasner, MD, MSCE**  
*Sidney Kimmel Comprehensive Cancer Center at Jefferson*

**11:45 AM Adjourn**

# AACI CRI Meeting 2026 Abstracts

Abstracts are organized by category and completion status, then in alphabetical order by cancer center.

## CATEGORIES:

**Clinical Trial Access (Network, Satellite, and Other Multisite Accrual Enhancement Efforts)**

**Clinical Trial Operations (Trial Start-up, Regulatory, Finance, Data Management, IITs)**

**Community Outreach and Engagement, and Community Representation and Inclusion**

**Cross-Cutting Innovation and Collaboration**

**Emerging Technology**

**Prioritization and Scientific Review**

**Quality Assurance**

**Training, Career Development, and Staff Retention**

## FIRST PLACE:

**Optimizing Data Collection in Investigator-Initiated Trials: Assessing Alignment Between Collected Data and Study Endpoints at UF Health Cancer Institute**

N. McGrew, L. Napier, T. George, P. Crispen, A. Ivey, E. Monari, A. Anderson, K. Barker, C. Cline, A. Kukulka, J. Walsh, S. Alford

UF Health Cancer Institute

## SECOND PLACE:

**My Opción: Enhancing Access to Cancer Clinical Trials and Education in the Hispanic/Latino Community Through Community Engagement**

L. Will, E. Nemecek

OHSU Knight Cancer Institute

## THIRD PLACE (TIE):

**NYU Prostate Cancer Automated Database (NYU Pro AD Pilot Project): Leverage AI in Operational Workflow**

A. Bhatt, V. Lam, J. Sommer, N. Chowdhury, R. Belenkaya, D.R. Wise

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

**Enhancing Scientific Review and Progress Monitoring to Improve Committee Management and Portfolio Oversight**

M. Brelsford, K. McCaffrey, K. Moffett

Moffitt Cancer Center

# 2026 Abstracts

## Clinical Trial Access (Network, Satellite, and Other Multisite Accrual Enhancement Efforts)

### 1. Clinical Trial Education for Community Cancer Center Sites

C. Poggio

UC Davis Comprehensive Cancer Center

### 2. Optimizing Trial Access Through Structured Molecular Review and Nurse Navigation

E. Bentlyewski, J. Hutchinson, T. Stockton, S. Santos La Paz, A. Pissey Keo, F. Brogan

Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center

### 3. Improving Clinical Trial Participation: a Transportation Support Initiative

S. McCoy, Z. Swainson, C. Abouzeid, D. Alerte, A. McCormack, A. McKnight, G. Gargano, B. Bodin, A. Joshi, J. Mehnert, B. Pothuri

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

## Clinical Trial Operations (Trial Start-up, Regulatory, Finance, Data Management, IITs)

### 4. Leveraging OnCore CTMS and SmartSheet for Accelerating Start-up

G. Subramanian, I. Isaac, M. Atteberry

Fred Hutch Cancer Center

### 5. The Diagnostic Audit: Scanning for Errors Before the FDA Does

V. LaBush, C. Zuccaro, H. Cressman, K. Schneider, R. Gorney

Karmanos Cancer Institute, Wayne State University

### 6. Integration of Clinical Trials With Nuclear Medicine for Radiopharmaceutical Treatments

N. Yang, C. Ordonez Ferri, B. Bodin, A. Joshi, J. Mehnert, B. Pothuri

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

### 7. Centralizing Weekly Admissions Communication to Reduce Email Burden and Enhance Coordination for Inpatient Clinical Research

C. Ordonez Ferri, B. Bodin, E. Ernest, A. Joshi, J. Mehnert, B. Pothuri

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

### 8. Enhancing Clinical Trial Operations Through Strategic Team Restructuring: Disease Group-Focused Specialization at Mayo Clinic Comprehensive Cancer Center

S. Voitik, A. Van Hyfte, V. Nguyen, M. Perrizo, A. Tavlirides, S. Brunson, A. Handlogten, T. Kiley-Ram, M. Warner, M. Ali, T. DiPina, N. Plouffe, T. Scales, L. Alfieri, J. McManus, R. Hagerty

Mayo Clinic Comprehensive Cancer Center

# 2026 Abstracts

---

**9. Implementation of Electronic Protocol Training and Response System Using Florence eBinders**

**A. Murphy, C. Collazo, M. Johnson, J. Jorski, K. McCaffrey**  
Moffitt Cancer Center

**10. Streamlining Amendment Process Through Development of a Standardized Process and Centralized Amendment Support Team**

**N. Ugrenovic, C. Lavender, A. Dean, J. Guerrero, M. Davis**  
Moffitt Cancer Center

**11. Loss to Follow-up: Policy Development and Formal Guidelines**

**M. Wakefield**  
OHSU Knight Cancer Institute

**12. Shifting Data Management Upstream: A Scalable Framework to Optimize Capacity, Quality, and Efficiency in Bone Marrow Transplant and Cell Therapy Trials**

**R. Atoum**  
OHSU Knight Cancer Institute

**13. From Static Scores to Strategic Staffing: Evolution of the ASCO Framework Into the PACT Near-Real-Time Workload Model**

**J. Shaub, X. Liu, C. Sowers, J. Liao, D. Shank, M. Joshi**  
Penn State Cancer Institute

**14. Sponsor-Proxy Infrastructure for Investigator-Initiated Trials: Enabling Translation of Natural Product Research in a Resource-Limited Cancer Center**

**X. Liu, D. Shank, J. Lü, M. Joshi**  
Penn State Cancer Institute

**15. Leveraging Artificial Intelligence and Workflow Automation to Streamline Cancer Committee Operations**

**C. Moussouris**  
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine

**16. Enhancing Visualization Into Study Start-up Using a Homegrown Time to Activation Dashboard**

**A. Ou, J. Reilly**  
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine

**17. Reducing NCTN Data Delinquency Through Structured Accountability and Centralized Monitoring**

**S. Ghandi**  
Stanford Cancer Institute

**18. Development and Implementation of a Cancer Center Acuity Model**

**A. Krone, S. Paton**  
The University of Arizona Cancer Center

**19. Decreasing Patient Financial Burden by Increasing Stipends and Travel Reimbursement**

**H. Coleman, R. Hayes, B. Scanlan, M. Kovak**  
UAMS Winthrop P. Rockefeller Cancer Institute

**20. “Out of Sight, Never Out of Mind”: Managing a Team You Can’t See But Fully Depend on**

**M. Gosky, W. Cunningham, T. Roberts**  
UK Markey Cancer Center

**21. Implementing a Team-Based Approach to Phase I Data Entry for Improvement of Data Timelines**

**L. Gordillo, S. Puz**  
University of Illinois Cancer Center

**22. Transforming Regulatory Operations: Driving Efficiency and Quality Through Advarra eReg at a Large Cancer Center**

**A. Barkman<sup>1</sup>, V. Chernyshev<sup>1</sup>, S. Karahukayo<sup>1</sup>, R. Villanueva<sup>1</sup>, J. Mead<sup>2</sup>, K. Wright<sup>2</sup>**  
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center<sup>1</sup>; Advarra<sup>2</sup>

**23. Building a Scalable DSMC Program for a Dynamic Research Enterprise**

**A. Peña**  
Winship Cancer Institute of Emory University

**24. Clinical Trial Project Managers: the Air Traffic Controllers of Study Activation**

**S. Raboin<sup>1</sup>, E. Stanley<sup>2</sup>, A. Gateman<sup>1</sup>**  
Yale Cancer Center, Yale School of Medicine<sup>1</sup>; Huron Consulting Group<sup>2</sup>

**25. Enhancing the Pathway to Treatment: a Structured Approach to Slot Management in Competitive Phase I Oncology Trials**

**J. Sobecks, C. Chukri, J. Tomer**  
Cleveland Clinic Cancer Center

**26. The Implementation of Central Data Tracking at the IUSCCC CTO**

**A. Stevens, S. Beeler, B. Hicks, L. Rohn, M. Contreras**  
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

**27. Enhancing Efficiency in Beacon Treatment Planning Through AI-Based Layout Generation**

**V. Ty, E. Love**  
Northwell Health Cancer Institute

**28. Establishing an IIT Committee to Streamline Oncology Investigator-Initiated Trials**

**M. Fortune**  
The Ohio State University Comprehensive Cancer Center – The James

# 2026 Abstracts

---

## 29. Streamlining Expanded Access: Implementation of a Centralized Management Model

A. Yost, V. Monga

UCSF Helen Diller Family Comprehensive Cancer Center

## 30. Beyond the Project Manager: Developing a Prioritization Decision Framework to Optimize Protocol Amendment Processing

K. Barker, L. Brown, W. Brown-Porter, A. Kukulka, D. Veal, A. Anderson, E. Monari, C. Cline, P. Crispen

UF Health Cancer Institute

## 31. Smartsheet in Action: Boosting Visibility and Improving Transparency Identifies Barriers to Reduce Study Activation Timelines

K. Nguyen, T. VandenBosch

Winship Cancer Institute of Emory University

## 32. Not All Studies Are Created Equal: a Method to Track Regulatory Service Staffing

S. Faulkner, N. Cassim, A. Hammond, D. Tait, D. Keir, L. Thomas

City of Hope Comprehensive Cancer Center

## 33. Building a Dedicated Non-Therapeutic Trials Unit to Strengthen Non-Therapeutic Research in a Comprehensive Cancer Center

G. Nkogbu, L. Fortin, A. Wagh, B. Kemp

Fox Chase Cancer Center, Temple Health

## 34. The Financial and Operational Challenges of CAR T Therapy Expansion

S. Sands, K.B. Bouker, N. Hiltbrand, M. Mavredes

Georgetown Lombardi Comprehensive Cancer Center

## 35. Novel Study Start-up Agreement: Guarantee Compensation for Start-up Work Performed Prior to Clinical Trial Agreement While Reducing Study Start-up Timelines

N. Hiltbrand, M. Caffet, M. Mavredes

Georgetown Lombardi Comprehensive Cancer Center

## 36. Evaluating Different Large Language Model/AI Agents for the Ability to Summarize SUSAR Reports

R. Lush, A. Barnett, A. Putur, A. Lucas, B. Sebsebie, L. Obara

GW Cancer Center

## 37. Building Institutional Infrastructure for Investigator-Initiated Treatment Trials

C. Charlton

Hollings Cancer Center, Medical University of South Carolina

## 38. Fast Track: Fine-Tuning an Accelerated Activation Program

K. Kallas, N. Catti, M. Huber, A. Joshi, J. Mehnert, B. Pothuri

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

## 39. Optimizing Oncology Trial Data Management Through Vendor Support

B. McGough<sup>1</sup>, A. Joshi<sup>1</sup>, L. Drake<sup>2</sup>, J. Mehnert<sup>1</sup>, B. Pothuri<sup>1</sup>

<sup>1</sup>Laura and Isaac Perlmutter Cancer Center at NYU Langone Health; <sup>2</sup>Omega Healthcare Management Services

## 40. Customizing Enterprise Biobanking Software for Clinical Trial Management to Improve Efficiency

K. Weren, J. Salcedo, S. Ghosh, A. Joshi, B. Pothuri

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

## 41. A Phased, Disease-Aligned Staffing Model Incorporating Protocol Complexity in a Multisite Cancer Center

E. Mederos<sup>1</sup>, D. Brackman<sup>1</sup>, M. Redzic<sup>2</sup>

<sup>1</sup>LSU LCMC Health Cancer Center; <sup>2</sup>Huron Consulting Group

## 42. Global Expansion: Activation of a Multicenter Phase II Immunotherapy Clinical Trial in Nigeria

C. Friedman<sup>1</sup>, J. Walkley<sup>1</sup>, M. Warren<sup>1</sup>, F. Balogun<sup>1</sup>, P. Kingham<sup>1</sup>, O. Alatise<sup>2</sup>, F. Abdulkareem<sup>3</sup>, T. Adewole<sup>4</sup>, Z. Yunusa-Kaltungo<sup>4</sup>, C. Olcese<sup>1</sup>, H. Pham<sup>1</sup>, C. Houston<sup>1</sup>

<sup>1</sup>Memorial Sloan Kettering Cancer Center; <sup>2</sup>Obafemi Awolowo University Teaching Hospital;

<sup>3</sup>College of Medicine, University of Lagos & Lagos University Teaching Hospital;

<sup>4</sup>MedServe LUTH Cancer Centre

## 43. Implementation of a Non-Therapeutic Research Office at an NCI-Designated Cancer Center

T. Hoffert, N. Naas

Moffitt Cancer Center

## 44. Utilization of Dual PI Model for Non-Oncology CAR T Clinical Trials at Standalone and Matrix Cancer Centers: Best Practices From Moffitt Cancer Center and Meyer Cancer Center at Weill Cornell

A. Shrewsbury<sup>1</sup>, A. Voorhees<sup>1</sup>, L. Pettiford<sup>1</sup>, H. Anderson<sup>1</sup>, L. Kelaher<sup>1</sup>, F. Oladapo<sup>1</sup>, M. Ugrenovic-Petrovic<sup>1</sup>, J. Lebsack<sup>1</sup>, A. Cutler<sup>2</sup>, R. Mitto<sup>2</sup>, L. Orvieto<sup>2</sup>, N. Santos<sup>2</sup>, D. Guarneri<sup>2</sup>, J. McConnell<sup>2</sup>

<sup>1</sup>Moffitt Cancer Center; <sup>2</sup>Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine

## 45. Rapid Activation Pathway: Speeding Through Study Start-up

L. Rohn, M. Contreras, L. Segó, G. Lander, T. Lautenschlaeger, A. Turk

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

# 2026 Abstracts

## 46. Building Capacity and Operationalizing Hybrid and Fully Decentralized Clinical Trials in Community Oncology: a Thematic Analysis of Expert Roundtable Discussions

A. Benson III<sup>1</sup>, C. Trachtenbroit<sup>2</sup>, N. Colwell<sup>2</sup>, L. Black<sup>3</sup>, S. Beg<sup>4</sup>, D. Friedman<sup>5</sup>, K. Kipping-Johnsson<sup>6</sup>, R. Kottschade<sup>7</sup>, B. McKelvey<sup>8</sup>, J. Moehle<sup>9</sup>, J. Myles<sup>10</sup>, E. Pierce<sup>11</sup>, A. Sah<sup>12</sup>, N. Stout<sup>13</sup>, W. Vogel<sup>14</sup>, E. Plotkin<sup>2</sup>

<sup>1</sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University; <sup>2</sup>Association of Cancer Care Centers; <sup>3</sup>Sanford Health; <sup>4</sup>Simmons Comprehensive Cancer Center, UT Southwestern Medical Center; <sup>5</sup>Durham VA Medical Center; <sup>6</sup>The University of Chicago Medicine Comprehensive Cancer Center; <sup>7</sup>Mayo Clinic Comprehensive Cancer Center; <sup>8</sup>LUNGEvity Foundation; <sup>9</sup>Huntsman Cancer Institute at the University of Utah; <sup>10</sup>Decentralized Trials & Research Alliance;

<sup>11</sup>HonorHealth Research Institute; <sup>12</sup>AS Pharma Advisors; <sup>13</sup>American Cancer Society;

<sup>14</sup>Advanced Practitioner Society for Hematology and Oncology

## 47. A New Enrollment Barrier: Data Entry

M. DiMeglio, K. Senter

Sidney Kimmel Comprehensive Cancer Center at Jefferson

## 48. Expediting Start-up Timelines by Dedicating a Start-up Specific Project Manager for Early-Phase Research

L. Farnon, B. Scruggs, T. Newhall, K. Herman

Sidney Kimmel Comprehensive Cancer Center at Jefferson

## 49. Supporting IIT Research Through the Lens of ClinicalTrials.gov Registration and Results Reporting Requirements

H. Derr, Z. Delgado, J. Frazier

Sidney Kimmel Comprehensive Cancer Center at Jefferson

## 50. People, Not Just Processes: Reimagining the Study Start-up Lifecycle

B. Scruggs, N. Khadke, L. Farnon, J. Gallagher, K. Herman

Sidney Kimmel Comprehensive Cancer Center at Jefferson

## 51. Developing a Standardized Data Management Framework to Improve Query Lifecycle Efficiency in a Newly-Established Site Disease Group

B. Soni

Sylvester Comprehensive Cancer Center, University of Miami

## 52. Standardizing EDC Case Report Form Development in a 21CFR P.11 Compliant EDC

R. Stillman, C. Schweitzer, K. Linsenmeyer

The Ohio State University Comprehensive Cancer Center - The James

## 53. Elevating Trial Operations: Implementing EHR to EDC Interoperability to Reduce Site Burnout and Data Entry Burden

S. Annis

The University of Kansas Cancer Center

## 54. The Evolution of IRB Submissions: Streamlining IRB Amendment Submission Workflows for Local Implementation Utilizing Oncore

R. Perry, B. Scanlan, M. Kovak, A. Holley

UAMS Winthrop P. Rockefeller Cancer Institute

## 55. Development and Implementation of Patient Education and Coordinator Training to Optimize Microbiome Specimen Collection and Tracking

M. Lunin, P. Gurjar, A. Gunnett, A. Kukulka, E. Monari, P. Crispen, T. George

UF Health Cancer Institute



## 56. Optimizing Data Collection in Investigator-Initiated Trials: Assessing Alignment Between Collected Data and Study Endpoints at UF Health Cancer Institute

N. McGrew, L. Napier, T. George, P. Crispen, A. Ivey, E. Monari, A. Anderson, K. Barker, C. Cline, A. Kukulka, J. Walsh, S. Alford

UF Health Cancer Institute

## 57. Oncology Clinical Trial Incentivized Reward Program: Driving Precision Accrual, Faster Activation, and High-Quality Execution

T. Roberts, G. Duvall, M. Gosky, W. Cunningham

UK Markey Cancer Center

## 58. From Idea to Award: Embedding Funding Strategy Into Clinical Development Workflows

A. Camp, K. Quinn, K. Ashcraft, E. Zewdie, V. Lippuner, E. Bowie, L. Kiefer

UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

## 59. Operationalizing the Hybrid Trial: UNC LCCC's Multi-System Compliance and Analytics Framework

S. Rachuri, L. Barry, S. Balu, C. Lee, J. Morrison, E. Crecelius

UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

## 60. From Fragmentation to Flow: Implementing a Comprehensive Smartsheet® Framework for IIT Management

T. Cull, T. Drumm, J. Figura, S. Hill, A. Martin

University of Colorado Cancer Center

## 61. From 216 to 88 Days: Optimizing Clinical Trial Activation Through an Operations-Driven Approach

C. Garza, D. Kitterman

University of Illinois Cancer Center

## 62. From Repository to Lifecycle Management: Transforming Regulatory Oversight Through eReg Implementation

E. Cebula

Willmot Cancer Institute, UR Medicine

# 2026 Abstracts

## 63. Accelerating Consent to Enrollment: Initiatives and Escalation Plans to Reduce Time to Initiation of Treatment

L. Schilling, E. Barton-Judson, B. Burton, M. Holmes, N. Meer, M. Stoddart, T. Whitfield, P. Newlands

Winship Cancer Institute of Emory University

## 64. Fixing the Funnel: Strategies to Minimize Screen Failure Rates

M. Zerdan<sup>1</sup>, J. Faraj<sup>1</sup>, T. McPherson<sup>2</sup>, A. Nooka<sup>1,3</sup>, P. Newlands<sup>1,3</sup>, T. Leal<sup>1,3</sup>

<sup>1</sup>Emory University School of Medicine; <sup>2</sup>Emory University School of Public Health;

<sup>3</sup>Winship Cancer Institute of Emory University

## 65. Accelerating Activation by Overcoming Roadblocks

J. Murphy<sup>1</sup>, A. Gateman<sup>1</sup>, A. Roshka<sup>1</sup>, J. Thurmond<sup>2</sup>

<sup>1</sup>Yale Cancer Center, Yale School of Medicine; <sup>2</sup>WCG

## Community Outreach and Engagement, and Community Representation and Inclusion



## 66. My Opción: Enhancing Access to Cancer Clinical Trials and Education in the Hispanic/Latino Community Through Community Engagement

L. Will, E. Nemecek

OHSU Knight Cancer Institute

## 67. Inclusion by Design: Protocol Development Strategies for Inclusion of Non-English-Speaking Participants in Investigator-Initiated Trials

M. Esplin, C. Moynier

Huntsman Cancer Institute at the University of Utah

## 68. A Dual Prospective–Retrospective Review Framework Enhancing Representation and Accessibility in Cancer Clinical Trials

T. Allen, W. Wray, V. Worthy, C. Riggan, J. Randall, M. Morse, A. Armstrong, C. Fornier, S. Belanger, S. Crankshaw, S. Patierno, K. Pollak, J. Freedman, T. Watts

Duke Cancer Institute

## 69. Nurse Navigators: Navigating the Path Towards Better Patient Compliance in Clinical Trials

E. Ernest, O. Vigran, C. Ferri, B. Bodin, A. Joshi, J. Mehnert, B. Pothuri

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

## 70. Decentralizing Clinical Trials for a Rural Population

S. Connelly, K. Rimmel, L. Black, E. Gibbons, S. Berry, T. Johnson

Sanford Burnham Prebys Medical Discovery Institute

## 71. Design and Execution of Community Trial Network: the Jefferson Enterprise SKCCC Experience

M. Brose, K. Herman, C. Degen, A. Scarpaci, J. Leighton, S. Patel, M. Walicki, J. Anderson, K. Kurowski, M. Kasner, C. Hubert

Sidney Kimmel Comprehensive Cancer Center at Jefferson

## Cross-Cutting Innovation and Collaboration

## 72. Coordination of Care: Developing a Framework for Successful Admission and Treatment of Inpatient Clinical Trial Patients — Oncology Setting

E. Williams, E. Siglinsky, S. Meletath, S. Garcia, Z. Jiang, S. Gonzales, S. Conley, C. Riley, S. Tatlock, N. Helton, T. Bear, C. Hong, S. Rashdan

Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

## 73. Measuring the Impact of Academic-Industry Partnership

L. Wall, S. Moellering, A. Spratt, M. Cooper, A. Nielsen, T. Tennant, M. Bowden, B. Stanford, M. Hightower, Z. Shelal, E. Mills

The University of Chicago Medicine Comprehensive Cancer Center

## 74. The Door is Always Open: Sustaining Staff Engagement Through Continuous Feedback

L. Segó, A. Stevens, A. Turk

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

## 75. The Clinical Research Innovation Consortium: a Multi-Stakeholder Model for Scalable Innovation in Clinical Research

A. Shah<sup>1</sup>, R. Panchal<sup>1</sup>, S. Terzulli<sup>1</sup>, C. Houston<sup>1</sup>, M. Warren<sup>1</sup>, J. Moehle<sup>2</sup>, M. Ugrenovic-Petrovic<sup>3</sup>, E. Herrscher<sup>4</sup>, C. Strouse<sup>5</sup>, P. Sabbatini<sup>1</sup>

<sup>1</sup>Memorial Sloan Kettering Cancer Center; <sup>2</sup>Huntsman Cancer Institute at the University of Utah;

<sup>3</sup>Moffitt Cancer Center; <sup>4</sup>Mount Sinai Tisch Cancer Center; <sup>5</sup>Holden Comprehensive Cancer Center, University of Iowa

## 76. Implementing a Health Literacy Assessment to Customize Patient Education and Improve Protocol Adherence

C. Schaefer, D. Thomas, D. Centofanti

Rutgers Cancer Institute

## 77. Improving Clinical Trial Recruitment Through Systematic Screening and Multidisciplinary Huddles

D. McBride, J. Bang, E. Biroc, C. Gepty, E. Anderson, B. Averion, M. Volpe, R. Roddy

Abramson Cancer Center of the University of Pennsylvania

## 78. National Clinical Trials Network Team Creation, Imagination, and Innovation

A. Mazur<sup>1</sup>, S. Atty<sup>1</sup>, K. Kleiber<sup>2</sup>, C. Muzyk<sup>2</sup>

<sup>1</sup>Karmanos Cancer Institute, Wayne State University; <sup>2</sup>Wayne State University

# 2026 Abstracts

## 79. Scaling Cellular Therapy Research: Implementing a Dedicated Transplant and Cellular Therapy Program for Non-Oncology Studies

A. Yakubov, K.A. Mangalindan, K. Pickens, M. Zimmermann, Z. Alvarez, B. Bodin, M. Abdul-Hay, J. Hsu, A. Joshi, J. Holahan, M. Bredella, B. Pothuri

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

## 3 TIE 80. NYU Prostate Cancer Automated Database (NYU Pro AD Pilot Project): Leverage AI in Operational Workflow

A. Bhatt, V. Lam, J. Sommer, N. Chowdhury, R. Belenkaya, D.R. Wise

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

## 81. A Structured Sponsor–Cancer Center Partnership Model to Improve Trial Operational Excellence (Visibility, Responsiveness, Activation Readiness) and Enable Innovation

A. Almazar<sup>1</sup>, T. Nghiem<sup>2</sup>

<sup>1</sup>Mayo Clinic Comprehensive Cancer Center, <sup>2</sup>AstraZeneca

## 82. The Clinical Trial Matching and Prescreening Task Force: a Work in Progress to Standardize and Enhance Prescreening and Referrals

M. Ugrenovic-Petrovic, J. Edelman, B. Tomas, A. Sansil, P. Olaore, S. Interrante, S. Fazilova, V. Sifontes, K. Sprenger, F. Bustamante, V. Ortega, A. Aminpour, L. Nardelli, J. Lebsack

Moffitt Cancer Center

## 83. Evaluating Program Metrics Through Dashboard Utilization

E. Nurminen, A. Lalanne

UCSF Helen Diller Family Comprehensive Cancer Center

## 84. Bridging the Resource Gap: Implementing EHR-to-EDC Integration in Investigator-Initiated Oncology Trials

A. Martin<sup>1</sup>, L. Snodgrass<sup>1</sup>, M. Lieber<sup>2</sup>, M. Boyd<sup>2</sup>, K. Moore<sup>2</sup>, D. Raine<sup>2</sup>, D. Binder<sup>1</sup>, T. Drumm<sup>1</sup>

<sup>1</sup>University of Colorado Cancer Center; <sup>2</sup>Paradigm Health

## 85. Unraveling Biospecimen Complexity in Clinical Trials: Benchmarking the Approach

K. Pavlik<sup>1</sup>; J. Voyten<sup>2</sup>, K. Bienfait<sup>3</sup>, E. Stoddard<sup>4</sup>, A. Ripston<sup>5</sup>

<sup>1</sup>Yale Cancer Center, Yale School of Medicine; <sup>2</sup>UPMC Hillman Cancer Center;

<sup>3</sup>Bristol Myers Squibb; <sup>4</sup>Eli Lilly and Company; <sup>5</sup>Biospecimen Management Consortium

## Emerging Technology

## 86. Embedding AI-Assisted Review of Unstructured Clinical Data Into Oncology Trial Operations

N. Bouvier, L. Yuravlivker, R. Singh, B. Young Kim, B. Liebe, M. Buckley, R. Panchal

Memorial Sloan Kettering Cancer Center

## 87. Improving Adverse Event Reporting With EHR-To-EDC: a Pilot Study

A. Patruno<sup>1</sup>, D. Cho<sup>1</sup>, M.O. Panzarella<sup>1</sup>, M. Buckley<sup>1</sup>, R. Panchal<sup>1</sup>, J. Lengfellner<sup>2</sup>, S. Terzulli<sup>1</sup>, P. Sabbatini<sup>1</sup>

<sup>1</sup>Memorial Sloan Kettering Cancer Center; <sup>2</sup>IgniteData

## 88. Real-World Evaluation of AI-Assisted Versus Manual Prescreening for Clinical Trial Eligibility

B. Grones, A. Truxon, M. Dohopolski, A. Rowell

Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

## 89. Optimizing Clinical Research Workforce Efficiency Through Technology-Driven Workload Assessment: an NCI-Designated Comprehensive Cancer Center TRIALNAV OASIS™ Pilot

W. Paez<sup>1</sup>, B. Muriera<sup>2</sup>, C. Mogul<sup>2</sup>, A. Bonafede<sup>1</sup>, D. Brown<sup>1</sup>, A. Gerchman<sup>1</sup>, M. Noroozi<sup>1</sup>, T. Kochukoshy<sup>1</sup>

<sup>1</sup>Fox Chase Cancer Center, Temple Health; <sup>2</sup>Temple Health

## 90. The Road to Paperless: a Look Inside Our Journey to Full Implementation of Advarra's Suite of Research Systems

F. Kerr, L. Rohn, V. Williams

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

## 91. Modernizing Regulatory Strategy for Next-Generation Oncology Technologies

A. Austin, R. Ellis, S. Grigsby, C. Kaur, L. Meeks, H. Pham, A. Yadav

Memorial Sloan Kettering Cancer Center

## 92. Leveraging ICD-10 Patient Volume Data to Improve Clinical Trial Feasibility and Portfolio Management

J. Edelman, B. Jones-Lombard, D. Jewett, E. Basic, M. Ugrenovic-Petrovic, J. Lebsack

Moffitt Cancer Center

## 93. Artificial Intelligence-Assisted Processing of Clinical Trial Safety Reports: a Pilot Implementation Study

A. Williams, B. Neter, K. Lauzier, S. Han

Northwell Health Cancer Institute

## 94. Leveraging Artificial Intelligence Based and EHR-Integrated Tool to Optimize Real-World Clinical Trial Matching in Oncology at an Academic Medical Center

C. Passaglia<sup>1</sup>, J. Lorch<sup>1</sup>, K. Opfer<sup>1</sup>, M.J. Gurley<sup>1</sup>, A. Zafirovski<sup>1</sup>, F. Lin<sup>1</sup>, A. Brikha<sup>1</sup>, J. Sugay<sup>1</sup>, T. Kumar<sup>2</sup>, S. Mahatma<sup>2</sup>, C. Nienhaus<sup>2</sup>, A. Folkers<sup>2</sup>, M. Hagen<sup>2</sup>, D. Mahalingam<sup>1</sup>, W. Gradishar<sup>2</sup>, S. Bagchi<sup>2</sup>, L. Bezler<sup>1</sup>, L. Schulte<sup>1</sup>, C. Yarbrough<sup>1</sup>, A. Gogunskaya<sup>1</sup>, P. Kartcheske<sup>1</sup>

<sup>1</sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University; <sup>2</sup>Vizlitics

# 2026 Abstracts

## 95. Streamlining Clinical Trial Matching by Developing a Trial Navigation Tool

B. Saraiya, N. Guan

Rutgers Cancer Institute

## 96. Leveraging the Electronic Medical Record for Clinical Research Documentation: Concomitant Medication Log

C. Carrigan, A. Rowell, R. David, A. Truxon, V. Barrera

Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

## Prioritization and Scientific Review

### 97. Enhancing Scientific Review and Progress Monitoring to Improve Committee Management and Portfolio Oversight

M. Brelsford, K. McCaffrey, K. Moffett

Moffitt Cancer Center

## 98. Operationalizing the Strategic Plan: a Predictive Framework for PRMS Protocol Prioritization

N. Mahaffey, D. Helms, A. Tydon, E. Kim

UC Davis Comprehensive Cancer Center

## 99. Maximizing Efficiency in Managing the Trial Activation Pipeline: Two-Year Follow-up

A. Skafel, N. Butowski, R. Aggarwal

UCSF Helen Diller Family Comprehensive Cancer Center

## 100. Enacting Stricter Accrual Monitoring Guidelines and Streamlining Automated Review Processes

L. Cox

Winship Cancer Institute of Emory University

## Quality Assurance

## 101. From Backlog to Zero: a Governance Redesign That Eliminated Year-End Monitoring Deferrals and Strengthened Institutional Oversight

A. Khan, L. O'Neil

Stanford Cancer Institute

## 102. Reframing Clinical Research Deviation Reporting: From Compliance Burden to Continuous Improvement

E. Dawkins, N. Surana, J. Brown

Sylvester Comprehensive Cancer Center, University of Miami

## 103. Use of REDCap Data Resolution Workflow to Facilitate and Track Internal Quality Assurance Queries at an Academic Site

S. Hotchkiss, K. Hensley, K. McNutt

The University of Kansas Cancer Center

## 104. Improving Audit Readiness at a Community Hospital Network Site Through a Structured Project Management and Quality Management Partnership

T. Mallock, L. Gammalo

Winship Cancer Institute of Emory University

## 105. Improving Medication Adherence and Decreasing Deviations and Audit Findings by Using a Standardized Health Literacy Screening

G. Watkins-Keller, T. Saunders

Rutgers Cancer Institute

## 106. Enhancing Quality Oversight in Cancer Clinical Trials: Real-Time Source Documentation Review

H. Martirosyan, N. Cassim, A. Hammond

City of Hope Comprehensive Cancer Center

## 107. Improving Rapid Event Reporting Compliance Through a Real-Time Monitoring Dashboard

M. Costa, N. Cassim, A. Hammond

City of Hope Comprehensive Cancer Center

## 108. Improving System-Wide Deviation Identification and Targeted Reduction Through a Live Monitoring Dashboard

W. Huang, N. Cassim, A. Hammond

City of Hope Comprehensive Cancer Center

## 109. Quality Assurance Internship Program: a Model to Improve Compliance in an Academic Clinical Trials Office

K. Stephens, L. Lujan, J. Moehle

Huntsman Cancer Institute at the University of Utah

## 110. Standardizing Monitoring Closure Decisions Within a Risk-Based Monitoring Framework

A. Granobles, C. Houston, K. Yataghene

Memorial Sloan Kettering Cancer Center

## 111. IDS-Led Medication Review at Screening to Support Eligibility Determination and Ensure Protocol Compliance and Subject Safety

A. Pradhan, J. Weeks, B. Mallinder, B. Valdes, M. Driggs, S.P. Ramirez, E. Herrera, P. Patel, R. Nair

Moffitt Cancer Center

## 112. Using an Improvement Rounds Workgroup to Maintain a Toolkit Library for Knight Clinical Research Management

J. Friedel, M. Thomas, D. Kreitner

OHSU Knight Cancer Institute

# 2026 Abstracts

---

## Training, Career Development, and Staff Retention

**113. Creating Career Progression Within CTO Regulatory Department Despite Organization Structural Restraints: the Senior Regulatory Compliance Coordinator Role**

V. Williams, M. Mullen, A. Vandiver

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

**114. Integrated Utilization of Monitoring and Quality Assurance Teams to Strengthen Oversight of Investigator-Initiated Trials**

V. Krines, J. Germain

Moffitt Cancer Center

**115. Building Comprehensive Blended Learning Models to Strengthen Clinical Trials Onboarding**

S. Riad, S. Ahmed, V. Ortega, C. Madden, M. Mitchell, L. Olson, J. Germain

Moffitt Cancer Center

**116. Facilitating Mentorships for Oncology Clinical Research Staff Through Mentorship Academy**

D. Kreitner, J. Friedel, T. Havnaer, K. Todd, P. Yates

OHSU Knight Cancer Institute

**117. Large Group Format Seminars for Clinical Research Staff Support, Engagement, and Continuing Education at OHSU Knight Cancer Institute**

D. Kreitner, J. Friedel, R. Lewis, C. Burgin

OHSU Knight Cancer Institute

**118. Designing a Scalable Oncology Clinical Research Workforce Infrastructure: a Competency-Integrated Model for Standardized Onboarding**

S. Baboun, E.A. Dawkins, J. Sanchez, M.M. Aulov, N.R. Bestard, C. Habaue, S. Bhukan, Y.D.L. Fuente, I. Marino, S.K. Chehal

Sylvester Comprehensive Cancer Center, University of Miami

**119. A Structured Study Coordinator Pipeline Model for Workforce Development and Operational Continuity**

L. Segó, L. Rohn

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

**120. Creating and Implementing an Introduction to Clinic Module for New Clinical Research Staff**

D. Kreitner, J. Friedel, M. Thomas, C. D'Andrea, C. Engbretson, C. Long, V. Abtin, M. Walton, R. Mahoney

OHSU Knight Cancer Institute

**121. Simulation-Based Training to Enhance Clinical Research Skilling: a Practice-Based Exploratory Pilot Study**

B. Snyder, J. Cabbagestalk, T. Brosche, N. Ellis, M. Joshi, M. Machtay, D. Shank

Penn State Cancer Institute

**122. Bridging the Gap Between Training and Practice: a Competency Checklist for Clinical Research Staff**

A. Moore

Winship Cancer Institute of Emory University

**123. Clinical Research Onboarding Program: Cultivating Competent and Confident Research Professionals**

J. Tugwell

City of Hope Comprehensive Cancer Center

**124. The Accountability Reset: a Tactical Framework for Empowering Clinical Research Leaders**

S. Belanger, A. Rice-Warren

Duke Cancer Institute

**125. A Continued Investment: Growth and Expansion of the Academic Committee Mentorship Program for Oncology Trainees at the Duke Cancer Institute**

C. Riggan, T. Allen, L.F. Diehl, N. DeVito, C. Hoimes, M. Horwitz, M.A. Morse, N.E. Ready, R.F. Riedel, G. Samsa, D.S. Van Mater, A. Armstrong

Duke Cancer Institute

**126. Implementing a Novel Centralized Education Leadership Model to Strengthen Clinical Research Workforce Development and Training Infrastructure**

A. Piskey Keo, E. Bentlyewski, F. Brogan

Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center

**127. Learning Evaluation & Advancement Plan (LEAP)**

H. Willis, S. Asche, F. Kerr

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

**128. Informed Consent Rubrics: Combining Policy, Procedure, and Education**

S. Roby, F. Kerr

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

**129. The Power of Support: Improving Clinical Trial Efficiency and Compliance Through a Clinical Research Assistant Role**

S. McCoy, E. Ernest, A. McCormack, O. Vigran, E. White, Z. Swainson, B. Bodin, A. Joshi, J. Mehnert, B. Pothuri

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

## 2026 Abstracts

---

**130. Implementing Developmental Roles to Strengthen Workforce Engagement and Research Operations**

M. Huber, B. McGough, F. Hsu, A. Joshi, N. Catti, J. Mehnert, B. Pothuri

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

**131. Development and Implementation of Cellular Immunotherapy-Specific Clinical Research Coordinator Training and Education Program**

A. Shrewsbury, M. Folsom, T. Swartzlander, K. Hildreth, E. Royster, M. Ugrenovic, J. Lebsack

Moffitt Cancer Center

**132. Turning Complexity Into Competency: Implementing a Structured Onboarding Framework for Clinical Trial Activation**

T. Lannon, A. Voorhees

Moffitt Cancer Center

**133. Structured Training and Staff Retention: a Three-Year Review**

A. Anderson, H. Avery, D. Hablitz, P. DeBlasio

O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham

**134. Investigator Orientation: an Educational Psychology Approach**

A. Macias

Stanford Cancer Institute

**135. A Structured, AI-Enabled Clinical Research Coordinator Certification Exam Preparation Program to Enhance Clinical Research Workforce Competency and Career Advancement: a Pilot in an Academic Cancer Center**

N. Hernandez Ortega

Sylvester Comprehensive Cancer Center, University of Miami

**136. The idea2Concept Workshop: an NIH R25-Supported Curriculum to Develop and Implement Investigator-Initiated Clinical Cancer Trial Concepts in Collaboration With AACI**

R. Wesolowski, D. Owen, A. McMahon, L. Wei, E. Klein, J. Hays, C. Verschraegen

The Ohio State University Comprehensive Cancer Center – The James

**137. Workload Assessments: Balancing Capacity, Performance, and Staff Satisfaction With Fiscal Responsibility**

J. Aguilar, T. Dooling, R. Javier, R. Gopalakrishnan, S. Moellering, J. Robertson

The University of Chicago Comprehensive Cancer Center

**138. Measuring Effectiveness of the Clinical Research Competency Training Program for Clinical Research Professionals**

S. Kang, A. Stungis, D. Lantero, G. Bromley, H. Williams, H. Patel, J. Aguilar, K. Hearn, L. Mathews

The University of Texas MD Anderson Cancer Center

**139. ONCO-GATOR: Oncology Networking, Coaching, and Opportunities – Guiding Advancement, Training, and Onboarding for Researchers**

J. Thomas, K. Hitchcock, A. Ivey, T. George, E. Monari, P. Crispin, L. Dixon

UF Health Cancer Institute

**140. Improving Clinical Research Coordinator Performance Through Structured Skills-Based Training and Assessment**

A. Kukulka, C. Cline, E. Monari, P. Crispin

UF Health Cancer Institute

**141. From Exposure to Retention: a Competency-Based Clinical Research Internship to Support Career Development and Workforce Stability**

A. Anderson, A. Kukulka, C. Cline, E. Monari, P. Crispin

UF Health Cancer Institute

**142. The Buddy System: No Employee Left Behind**

W. Cunningham, M. Gosky, K. Oram, T. Roberts

UK Markey Cancer Center

**143. Uniting Cancer Research Teams: the Impact of a Collaborative Education Series**

C. Wiess,<sup>1</sup> W. Paez,<sup>2</sup> T. Nghiem,<sup>3</sup> S. Edwards<sup>3</sup>

<sup>1</sup>Yale Cancer Center, Yale School of Medicine; <sup>2</sup>Fox Chase Cancer Center, Temple Health;

<sup>3</sup>AstraZeneca

## AACI CRI Supporters

AACI gratefully acknowledges support from the following:

### Premier Supporter



### Keynote Supporter



### Champion Supporter



### Silver Supporter



## AACI CRI Exhibitors

AACI gratefully acknowledges support from the following:



## AACI CRI Exhibitors

---

### Actalent

Actalent is a global leader in engineering and sciences services and talent solutions. We help visionary companies advance their engineering and science initiatives through access to specialized experts who drive scale, innovation, and speed to market. With a network of almost 30,000 consultants and more than 4,500 clients across the U.S., Canada, Asia, and Europe, Actalent serves many of the Fortune 500.

### Advarra

Advarra provides the platform, insights, and expertise that make clinical trials more efficient and connected. As the leading independent IRB, we bring more than 40 years of trusted oversight to the industry, setting the standard for ethical reviews while building the largest collection of digitized protocols and operational data. This combined intelligence guides the protocol's entire journey—from design through review, activation, and conduct—fueling a smarter, more adaptive research ecosystem.

Backed by decades of partnership with research sites, Advarra delivers the core systems and services that 50,000 investigators and their study teams depend on for optimal trial operations. Integrated with our solutions for study design, start-up, and conduct, these capabilities create a collaborative technology platform trusted by sponsors and CROs globally.

By designing AI-powered workflows that streamline operations, reduce administrative burden, and promote transparency for all study stakeholders, we're reimagining what's possible in clinical research.

### BioNTech

BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb; Duality Biologics; Genentech, a member of the Roche Group; Genmab; MediLink; OncoC4; and Pfizer.

### Elevate Clinical Research Solutions

Pioneered by the experts who first introduced outsourced coverage analysis, Elevate Clinical Research Solutions combines deep operational heritage with elite execution for the world's most sophisticated programs, including multiple NCI-Designated Cancer Centers. As a 100% U.S.-based extension of your site, we customize your workflows for coverage analysis, budgets, contracting, and CTMS builds to protect your revenue and match your exact risk tolerance. While the rest of the industry lags behind, our study-level project management actively accelerates site activation down to aggressive 60- and 90-day timelines with the collaboration of the site team. We deliver flawless, expert-level work products the first time, ruthlessly eliminating the costly downstream re-works that stall trials and strain sponsor relationships. Backed by our transparent pricing, our study model eliminates setup costs, meaning your weekly one-hour strategic weekly meetings and monthly KPI metric reporting are always included at no extra charge—ensuring zero financial surprises while freeing your staff to focus on their priorities.

### Florence Healthcare

Florence is the fastest-growing trial operations platform connecting 65,000+ study sites and 600+ life science leaders worldwide to advance cures for disease. As the eISF category leader, Florence delivers AI-first workflows that reduce risk from protocol to closeout. Loved by site teams for its intuitive interface and remote capabilities, Florence eliminates redundant work, ensures inspection readiness, and allows sites to focus on what matters most: patient care. Florence delivers real-time operational visibility, open collaboration, and site intelligence, providing a 7x return on investment for sites, sponsors, and CROs.

### Huron

Huron is a global professional services firm that collaborates with organizations to help solve their most complex challenges and achieve their most ambitious goals. Working across the private and public sectors, we partner closely with clients to improve performance, accelerate transformation, and unlock new opportunities for growth.

Our clients choose us because of our deep industry and technical expertise and proven track record of turning sound strategies into action. By combining practical experience, innovative thinking, and advanced analytics and technology, Huron helps organizations translate today's ideas into tangible results and long-term value.

## AACI CRI Exhibitors

---

### **IgniteData** (AACI Tech Gold member)

At IgniteData, we are laser-focused on eliminating the burden of manual data transfer for research sites. Archer, our virtual research assistant, is designed specifically to support your CRCs with getting data from source to sponsor. Today, Archer is utilized by 47% of NCI-Designated Comprehensive Cancer Centers and 8 of the top 10 U.S. News & World Report-ranked cancer centers. As a truly agnostic solution, Archer is actively running studies with multiple industry partners across platforms like Medidata Rave and Veeva, with Advarra EDC integration arriving later this year. By bridging the gap between sites and sponsors with a robust mapping engine, Archer streamlines data coordination to drastically reduce manual errors and ongoing queries. This seamless integration enhances overall productivity and data accuracy, empowering your study teams to refocus on what matters most: critical oncology research and the patient experience.

### **Medidata** (AACI Tech Gold member)

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating over 25 years of groundbreaking technological innovation across more than 38,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial datasets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata's seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Listen to our latest podcast, *from Dreamers to Disruptors*, and follow us on social media: [@Medidata](#).

### **Mint Medical**

Mint Medical develops advanced software solutions for oncology imaging and clinical research workflows. With mint Lesion for Clinical Trials, oncology teams, clinical trial offices, and investigators work in one structured environment for therapy response assessment, reporting, and trial coordination.

Our platform combines standardized oncology assessment workflows, configurable trial processes, and integrated operational tools to support efficient, reproducible, and compliant clinical trial execution. Available as a fully managed service or in-house deployment, mint Lesion helps sites streamline collaboration, accelerate turnaround times, and generate high-quality structured data for oncology research.

The Clinical Trial Request Portal provides a dedicated web-based interface that connects clinical trial coordination and imaging execution in a shared, transparent workflow. The portal enables streamlined trial intake, structured communication, task coordination, and centralized visibility across stakeholders, helping research teams manage growing trial complexity with greater efficiency and alignment.

### **nCartes**

nCartes is a transformational EHR-to-EDC cloud software platform. nCartes enables clinical research sites and sponsors to harness electronic health record systems (EHRs) to automate data capture for clinical trials, patient registries, cell manufacturing and more. nCartes sites report time and cost reductions in study data entry of as much as 50% while also materially reducing data entry mistakes and related work associated with source data verification. nCartes is a proud collaborator with the SWOG Cancer Research Network whose sites have also experienced considerable success with nCartes on SWOG trials. To learn more, please stop by the nCartes exhibit or contact [info@ncoup.com](mailto:info@ncoup.com).

### **Paradigm Health** (AACI Tech Gold member)

Paradigm Health has developed an AI-powered platform to streamline operations, accelerate portfolio growth, and expand patient access to clinical trials at partnering sites. Paradigm Health partners with health systems to accelerate and optimize end-to-end clinical trial operations, including sourcing high-value, well designed trials, increasing the pace of patient identification and recruitment, and reducing the burden of study data collection. Paradigm Health's network consists of community health systems, oncology practice networks, and academic medical centers (AMCs) across the United States, and ex-U.S. AMCs, including National Cancer Center Hospital East in Japan and Sheba Medical Center in Israel. The Paradigm Health platform is designed to enhance both the efficiency and scalability of clinical trials, while improving patient access to research and reducing burden on care teams.

Through a new collaboration with the U.S. Food and Drug Administration, The University of Texas MD Anderson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Amgen, and AstraZeneca are all using Paradigm Health's platform to dramatically accelerate trial review.

## AACI CRI Exhibitors

---

### TRIALNAV®

TRIALNAV is an AI-powered clinical research operations platform designed to help academic cancer centers, community research programs, and site networks optimize trial execution, workforce utilization, and financial performance. By transforming complex operational data into actionable intelligence, TRIALNAV provides real-time visibility into protocol workload, staffing capacity, productivity, trial portfolio performance, and budget forecasting. The platform enables research leaders to make data-driven decisions, reduce operational inefficiencies, expand research capacity, and accelerate patient access to clinical trials. TRIALNAV empowers organizations to move from reactive management to proactive operational excellence.

### Veeva

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences and clinical research industries. Committed to innovation, product excellence, and customer success, Veeva has more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging research sites.

### Verily

Verily Health is a data platform and AI company purpose-built for precision health. We combine deep clinical, regulatory, and technological expertise to provide our customers with patient-centric solutions that make health care more personal and precise. Verily Health solutions are designed to make health care data AI-ready and fit for purpose across care, research, and public health.

Built on Verily Pre, an AI-native platform for precision health, Viewpoint solutions innovate and transform research through gathering and curating real-world data to enable faster, more precise findings, and by providing tools for more efficient trial operations. Viewpoint connects participants, sites, and sponsors across the research lifecycle – cutting time to richer insights and breakthroughs.

### Vizlitics

Vizlitics provides comprehensive clinical decision support solutions, enabling care teams to run collaborative and streamlined clinical workflows from referral to surveillance on an EHR-integrated and AI-enabled platform.

### WCG

WCG is a global leader of solutions that measurably improve and accelerate clinical research. Biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and sites partner with us for our unmatched expertise, data intelligence, and purpose-built technology to make informed decisions and optimize study outcomes, while maintaining the highest standards of human participant protection. WCG raises the bar by pioneering new concepts, reimagining processes, fostering compliance and safety, and empowering those who perform clinical trials to accelerate the delivery of medical therapies and devices that improve lives.

### Yunu (AACI Tech Gold member)

Yunu is redefining how imaging powers clinical research. The company's intelligent, end-to-end workflow platform streamlines every stage of imaging-based trials—from image capture and reader assignment to adjudication and data export—ensuring scientific integrity and operational efficiency. Trusted by life sciences, pharmaceutical, cancer centers, and research organizations worldwide, Yunu empowers teams to manage complex imaging studies with clarity, confidence, and speed.



Yunu eliminates site error rates as high as **50%**

Yunu's clinical trial imaging platform streamlines and harmonizes workflows, connects stakeholders in a collaborative environment, and ensures accurate, complete assessments before every patient visit.


New!

## Yunu De-ID & Export

A Simpler Way to Anonymize & Export Trial Data

- ✓ Role-Based Export
- ✓ Optional De-ID on Export
- ✓ Less Manual Effort
- ✓ Greater Workflow Control

Connect with us today!

 [yunu.io](https://yunu.io)

 [info@yunu.io](mailto:info@yunu.io)



REGISTER TODAY

# 2026 AACI/CCAF Annual Meeting

October 25-27, 2026



Chicago Marriott Downtown Magnificent Mile

SAVE THE DATE!



## 19th Annual AACI Clinical Research Innovation (CRI) Meeting

June 28-30, 2027

Loews Chicago O'Hare Hotel • Rosemont, IL

# Thank you

## 2026 Corporate Roundtable Members

**Genentech**  
A Member of the Roche Group

 **GILEAD**

 **Kite**

**Johnson & Johnson**

*Lilly*

 **MERCK**

 **NOVARTIS**

**PhARMA**  
RESEARCH • PROGRESS • HOPE

  
**AACI CRI**  
Clinical Research Innovation

# THANK YOU!

See you next year.

# Thank you

## to the 2026 AACI Tech Gold members

  
**CARIS**  
LIFE SCIENCES

 **IgniteData**

 **MEDIDATA**

 **Paradigm Health**

**yunu**